Decreased need for RRT in liver transplant recipients after pretransplant treatment of hepatorenal syndrome-type 1 with terlipressin.

Autor: Weinberg EM; University of Pennsylvania, Philadelphia, Pennsylvania, USA., Wong F; University of Toronto, Toronto, Ontario, Canada., Vargas HE; Mayo Clinic, Phoenix, Arizona, USA., Curry MP; Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA., Jamil K; Mallinckrodt Pharmaceuticals, Bridgewater, New Jersey, USA., Pappas SC; Orphan Therapeutics, LLC, Longboat Key, Florida, USA., Sharma P; University of Michigan, Ann Arbor, Michigan, USA., Reddy KR; University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Publikováno v: Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society [Liver Transpl] 2024 Apr 01; Vol. 30 (4), pp. 347-355. Date of Electronic Publication: 2023 Oct 09.

The Effect of Terlipressin on Renal Replacement Therapy in Patients with Hepatorenal Syndrome.

Autor: Velez JCQ; Department of Nephrology, Ochsner Health, New Orleans, Louisiana.; Ochsner Clinical School, The University of Queensland, Brisbane, Queensland, Australia., Wong F; Department of Medicine, University of Toronto, Toronto, Ontario, Canada., Reddy KR; Division of Gastroenterology and Hepatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania., Sanyal AJ; Division of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia., Vargas HE; Division of Gastroenterology and Hepatology, Mayo Clinic, Phoenix, Arizona., Curry MP; Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts., Gonzalez SA; Department of Medicine, Baylor Scott & White All Saints Medical Center, Fort Worth, Texas., Pappas SC; Orphan Therapeutics LLC, Longboat Key, Florida., Jamil K; Mallinckrodt Pharmaceuticals, Bridgewater, New Jersey.

Publikováno v: Kidney360 [Kidney360] 2023 Aug 01; Vol. 4 (8), pp. 1030-1038. Date of Electronic Publication: 2023 May 05.

In vitro binding and receptor-mediated activity of terlipressin at vasopressin receptors V1 and V2

Autor: Jamil K, Pappas SC, Devarakonda KR

Publikováno v: Journal of Experimental Pharmacology, Vol Volume 10, Pp 1-7 (2017)

Khurram Jamil,1 Stephen Chris Pappas,2 Krishna R Devarakonda1 1Clinical Development, Mallinckrodt Pharmaceuticals, Bedminster, 2Orphan Therapeutics, LLC, Lebanon, NJ, USA Abstract: Terlipressin, a synthetic, systemic vasoconstrictor with selective ac

Externí odkaz: https://doaj.org/article/b35034da55b449109788f139ea56a68c

Reply.

Autor: Sigal SH; Division of Hepatology, Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York., Pappas SC; Department of Clinical Development and Scientific Affairs, Orphan Therapeutics LLC, Longboat Key, Florida., Jamil K; Mallinckrodt Pharmaceuticals, Bridgewater, New Jersey.

Publikováno v: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association [Clin Gastroenterol Hepatol] 2023 Nov; Vol. 21 (12), pp. 3198-3199. Date of Electronic Publication: 2023 May 20.

Corrigendum

Autor: Boyer TD, Medicis JJ, Pappas SC, Potenziano J, Jamil K

Publikováno v: Open Access Journal of Clinical Trials, Vol 2012, Iss default, Pp 59-60 (2012)

Boyer TD, Medicis JJ, Pappas SC, Potenziano J, Jamil K. A randomized, placebo-controlled, double-blind study to confirm the reversal of hepatorenal syndrome type 1 with terlipressin: the REVERSE trial design. Open Access Journal of Clinical Trials. 2

Externí odkaz: https://doaj.org/article/5da08423c22b42dfa711d7137acf4436